Search results for "Asses"

showing 10 items of 5931 documents

Cadmium mass measurements between the neutron shell closures at N=50 and 82

2010

International audience; The mass values of the neutron-deficient cadmium isotopes 99−109Cd and of the neutronrich isotopes 114,120,122−124,126,128Cd have been measured using ISOLTRAP. The behavior of the separation energies of the cadmium isotopes from N = 50 to 82 is discussed.

CadmiumIsotopehigh-precision mass measurementsChemistryStable isotope ratioPenning trapRadiochemistrychemistry.chemical_element020206 networking & telecommunications02 engineering and technology[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]ISOLTRAP7. Clean energyISOLTRAPcadmium massesIsotope separationlaw.inventionlawIsotopes of cadmium0202 electrical engineering electronic engineering information engineering020201 artificial intelligence & image processingNeutron21.10.Dr 21.30.Fe 27.60.+j 32.10.BiNucleon
researchProduct

LIFE AForClimate: approcci predittivi per una selvicoltura del faggio in sintonia con il clima

2019

Numerosi studi hanno dimostrato che l’incremento delle temperature medie stagionali e le variazioni nel regime stagionale delle precipitazioni influenzano direttamente la variabilità di crescita dei popolamenti forestali. Conoscere la risposta delle foreste alla variabilità del clima è propedeutica a calibrare gli interventi selvicolturali per garantire minore stress alle piante e una migliore efficienza ecosistemica. Il progetto LIFE AForClimate (LIFE15 CCA/IT/000089 - Adaption of FORest management to CLIMATE variability: an ecological approach) mira a fornire soluzioni concrete per realizzare una gestione forestale efficace nell’adattamento ai cambiamenti climatici e definire un metodo pe…

Cambiamento climatico Monitoraggio climatico Selvicoltura adattativa FaggioSettore AGR/05 - Assestamento Forestale E Selvicoltura
researchProduct

Origin of clay minerals in soils on pyroclastic deposits in the island of Lipari (Italy)

2005

The island of Lipari (Italy) is characterized by calc-alkaline to potassic volcanism and a Mediterranean-type climate. The mineralogical and chemical features of two different soil profiles with ages of 92,000 and 10,000–40,000 y, respectively, have been investigated. There were no Andisols, but Vitric and Vertic Cambisols have developed at both sites. Although the morphology of the soils was similar, remarkable differences in the clay mineralogy between the two sites were observed. The site with the Vitric Cambisol was associated with the weathering sequence: glass → halloysite → kaolinite or interstratified kaolinite-2:1 clay minerals. Both sites had smectite in the clay fraction and, to …

CambisolGeochemistrySoil ScienceMineralogyWeatheringAndisols geochemistry montmorillonite glasses kaolinite sheet silicates Italy Cambisols clay mineralogy Europe silicates soils halloysite Lipari Islands clay minerals igneous rocks Lipari Island smectite metasomatism weathering Sicily Italy volcanic rocks Southern Europeengineering.materialHalloysitechemistry.chemical_compoundMontmorillonitechemistrySettore AGR/14 - PedologiaGeochemistry and PetrologySoil waterEarth and Planetary Sciences (miscellaneous)engineeringSoil horizonKaoliniteClay mineralsGeologyWater Science and Technologyclays and clay minerals
researchProduct

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead

2015

Goodson, William H. et al.

Cancer ResearchCarcinogenesis[SDV]Life Sciences [q-bio]METHOXYCHLOR-INDUCED ALTERATIONSReviewPharmacologyMESH: Carcinogens EnvironmentalCarcinogenic synergiesChemical mixturesNeoplasmsMESH: AnimalsMESH: NeoplasmsCarcinogenesiRisk assessmentCancerACTIVATED PROTEIN-KINASESMedicine (all)Low dose1. No povertyCumulative effectsBREAST-CANCER CELLSGeneral MedicineEnvironmental exposureMESH: CarcinogenesisBIO/10 - BIOCHIMICAEPITHELIAL-MESENCHYMAL TRANSITION3. Good health[SDV] Life Sciences [q-bio]Environmental CarcinogenesisESTROGEN-RECEPTOR-ALPHARisk assessmentHumanMESH: Environmental ExposureENDOCRINE-DISRUPTING CHEMICALSTARGETING TISSUE FACTOR[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPrototypical chemical disruptorsExposure[SDV.CAN] Life Sciences [q-bio]/CancerEnvironmental healthmedicine[SDV.EE.SANT] Life Sciences [q-bio]/Ecology environment/HealthCarcinogenEnvironmental carcinogenesis[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthMESH: HumansAnimalPOLYBROMINATED DIPHENYL ETHERSCancerEnvironmental Exposuremedicine.diseaseMESH: Hazardous SubstancesCarcinogens EnvironmentalMIGRATION INHIBITORY FACTORVASCULAR ENDOTHELIAL-CELLSHazardous SubstanceNeoplasmCarcinogenesis
researchProduct

Accurate classification of childhood brain tumours by in vivo H-1 MRS - A multi-centre study

2013

Aims: To evaluate the accuracy of single-voxel Magnetic Resonance Spectroscopy (1H-MRS) as a non-invasive diagnostic aid for pediatric brain tumours in a multi-national study. Our hypotheses are (1) that automated classification based on 1H-MRS provides an accurate non-invasive diagnosis in multi-centre datasets and (2) using a protocol which increases the metabolite information improves the diagnostic accuracy. Methods: 78 patients under 16 years old with histologically proven brain tumours from 10 international centres were investigated. Discrimination of 29 medulloblastomas, 11 ependymomas and 38 pilocytic astrocytomas was evaluated. Single-voxel MRS was undertaken prior to diagnosis (1.…

Cancer ResearchPathologymedicine.medical_specialtyClinical assessmentPilocytic AstrocytomasDiagnostic accuracyDiagnostic aidIn vivo1H MRSPattern recognitionNon-invasive diagnosismedicineMulti centrePre-surgery diagnosis assessmentbusiness.industryEcho timeLinear discriminant analysisClassificationTranslational research Tissue engineering and pathology [ONCOL 3]Multi-centre studyOncologyFISICA APLICADAFeature extractionPaediatric brain tumoursStimulated echoNuclear medicinebusinessEuropean Journal of Cancer
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

Multiple primary neoplasms in childhood: data from the German children’s cancer registry

1998

Abstract The German Children’s Cancer Registry (GCCR) has documented all malignancies during the first 15 years of life in Germany since 1980. In a series of 20 388 cancer cases to the end of 1995, 127 children with multiple primary neoplasms up to the age of 15 years were identified. The children were monitored for 82 591 person-years with a mean observation time of 4.1 years. Relative and cumulative risk for the occurrence of second malignant neoplasms were estimated only for the first 15 years of life, as follow-up data beyond childhood are incomplete and valid data on the incidence of cancer in adolescents and adults are not available in Germany. The overall standardised incidence ratio…

Cancer ResearchPediatricsmedicine.medical_specialtyAdolescentMalignancyRisk AssessmentNeoplasms Multiple PrimaryGermanRisk FactorsGermanymedicineHumansRegistriesChildbusiness.industryIncidenceIncidence (epidemiology)Infant NewbornAbsolute risk reductionInfantCancerNeoplasms Second Primarymedicine.diseaselanguage.human_languageCancer registryRisk EstimateOncologyEl NiñoChild PreschoollanguagebusinessEuropean Journal of Cancer
researchProduct

O78. Which phenotype adds to cardiovascular risk assessment? Lessons from the Gutenberg heart study: A prospective, population-based cohort study in …

2008

Cancer ResearchPediatricsmedicine.medical_specialtyPhysiologybusiness.industryClinical BiochemistryRetrospective cohort studyBiochemistryPhenotypePopulation based cohortCardiovascular epidemiologymedicineRisk assessmentbusinessNitric Oxide
researchProduct

Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

2013

Human papillomavirus (HPV) 58 accounts for a notable proportion of cervical cancers in East Asia and parts of Latin America, but it is uncommon elsewhere. The reason for such ethnogeographical predilection is unknown. In our study, nucleotide sequences of E6 and E7 genes of 401 HPV58 isolates collected from 15 countries/cities across four continents were examined. Phylogenetic relationship, geographical distribution and risk association of nucleotide sequence variations were analyzed. We found that the E6 genes of HPV58 variants were more conserved than E7. Thus, E6 is a more appropriate target for type-specific detection, whereas E7 is more appropriate for strain differentiation. The frequ…

Cancer ResearchSettore MED/07 - Microbiologia E Microbiologia Clinicacervical cancerSettore MED/06 - Oncologia MedicaPapillomavirus E7 ProteinsUterine Cervical NeoplasmsCervix UteriphylogenyPolymerase Chain ReactionViralPapillomaviridaePapillomaviridaePhylogenyCancerOncogene ProteinsCervical cancerGeneticsTumorGeographybiologyNucleic acid sequenceDNA NeoplasmPrognosisInfectious DiseasesOncologyHIV/AIDSFemaleHPVhuman papillomavirus type 58 E6 and E7 sequence variationsOncology and CarcinogenesisCervical intraepithelial neoplasiaRisk AssessmentArticleVaccine Relatedoncogenic riskClinical ResearchPhylogeneticsGenetic variationGeneticsBiomarkers TumormedicineHumansOncology & CarcinogenesisGenePreventionPapillomavirus InfectionsGenetic VariationInternational AgenciesDNAOncogene Proteins ViralOdds ratioUterine Cervical Dysplasiamedicine.diseasebiology.organism_classificationVirologyvariantNeoplasmSexually Transmitted InfectionsCapsid ProteinsBiomarkersFollow-Up Studies
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct